News

Marinus is developing ganaxolone IV for the treatment of status epilepticus, a life-threatening medical emergency associated with high mortality and limited treatment options. The data was presented during

The trial, Expedition-4, enrolled 104 patients including 85 who were receiving dialysis at enrollment, 20 with compensated cirrhosis and 44 who were not cured with sofosbuvir with ribavirin

Braeburn Pharmaceuticals and Camurus announced the positive top-line results from the pivotal phase 3 randomized, double-blind, double-dummy, active controlled trial of weekly and monthly injections of buprenorphine. Apart

Enrollment in the 60-patient open label Phase 3 trial is ongoing across multiple sites in the United States, trial completion is expected in the first half of 2017,

The programme is focused on advanced liver cancer where current chemotherapeutic treatment options are limited and the typical survival period is six months.  Midatech is pursuing improved forms

LIQUENT InSight for IDMP is the newest module added to PAREXEL’s Regulatory Information Management (RIM) platform.  Beginning in 2018, the European Medicines Agency (EMA) will require biopharmaceutical companies to submit

PKC412 is indicated to treat AML in newly-diagnosed adults with an FMS-like tyrosine kinase-3 (FLT3) mutation, as well as for the treatment of advanced systemic mastocytosis (SM). The

Parsabiv is a calcimimetic agent where a healthcare provider can administer it intravenously three times per week at the end of a hemodialysis session. A calcimimetic is a

CPI-444 is a selective and potent inhibitor of the adenosine A2A receptor. The data were presented today in a poster session by John Powderly II, M.D., founder and